Before administering a prescribed emetic, which of the following would the nurse need to assess?

Choice A rationale:

Macrolides are typically broad-spectrum antibiotics, not narrow-spectrum. They are effective against a wide range of bacteria, making them a valuable option for various infections.

Choice B rationale:

Macrolides are generally well-tolerated, and they are not contraindicated in clients with renal dysfunction. In fact, macrolides like azithromycin are often preferred in such cases due to their minimal renal excretion.

Choice C rationale:

Macrolides, specifically erythromycin, have been associated with ototoxicity, which can lead to hearing impairment. This side effect is relatively rare but can occur, especially with high doses or prolonged use. It's important for healthcare providers to monitor for this potential adverse effect.

Choice D rationale:

Macrolides are often used as an alternative for clients who are allergic to penicillins, so they can be used in this population when appropriate. The cross-reactivity between these drug classes is relatively low, and macrolides can be a suitable choice for penicillin-allergic individuals.

Choice A rationale:

Protease inhibitors are a category of antiretroviral drugs used in the treatment of HIV. They work by affecting an enzyme called protease, which is necessary for the maturation of new viral particles. By inhibiting protease, these drugs prevent the formation of mature, infectious HIV particles.

Choice B rationale:

Reverse transcriptase inhibitors, including both nucleoside and non-nucleoside variants, target the enzyme reverse transcriptase. This enzyme is involved in the conversion of HIV RNA into DNA, an essential step in the viral life cycle. However, it's not about preventing the maturation of new viral particles, as mentioned in the question.

Choice C rationale:

Nonnucleoside reverse transcriptase inhibitors (NNRTIs) also inhibit the reverse transcriptase enzyme, but they do so differently than protease inhibitors. While they are vital in HIV treatment, they do not specifically target the maturation of viral particles.

Choice D rationale:

Integrase inhibitors target the enzyme integrase, which is involved in the integration of viral DNA into the host cell's DNA. This step is crucial in the HIV life cycle, but it's not related to the maturation of new viral particles.